Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer TranscriptSeeking Alpha • 06/01/26
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate CancerBusiness Wire • 05/30/26
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid ChemotherapyBusiness Wire • 05/29/26
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast CancerBusiness Wire • 05/21/26
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder CancerBusiness Wire • 05/15/26
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for InvestorsZacks Investment Research • 05/07/26
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a BetZacks Investment Research • 05/05/26
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic CancersBusiness Wire • 04/28/26
Veracyte (VCYT) Recently Broke Out Above the 50-Day Moving AverageZacks Investment Research • 04/27/26
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/26